|View printer-friendly version|
SOUTH SAN FRANCISCO, Calif., May 03, 2010 (BUSINESS WIRE) --Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company's vice president of investor relations and corporate communications, will present at the Ninth Annual JMP Securities Research Conference at 1:30 p.m. PDT / 4:30 p.m. EDT on Monday, May 10, 2010 in San Francisco. Mr. Butler will discuss the company's corporate strategy, development pipeline, and financial outlook.
The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
SOURCE: Exelixis, Inc.
Charles Butler, 650-837-7277
and Corporate Communications
DeDe Sheel, 650-837-8231